Phase Biolabs Ltd
Supplementary note to the original financial statements
for the year ended 31 December 2025
These revised financial statements replace the original financial statements for the year ended 30th September 2026 and are now the statutory accounts. They have been prepared as at the date of the original financial statements and do not deal with events between that date and the date of revision. These revised financial statements correct a misstatement of intercompany expenses in the original financial statements.

This supplementary note was approved by the director and authorised for issue with the original financial statements on 26 October 2026 and signed by:
Mr D Ortega Raymundo, Director
Company registration number: 12602104
Annual report and unaudited financial statements
for the year ended 31 December 2025
for
Phase Biolabs Ltd
Pages for filing with the Registrar
Company registration number: 12602104
Phase Biolabs Ltd
Balance sheet
as at 31 December 2025
2025 2024
Note £ £ £ £
Fixed assets
Tangible assets 4 120,567 259,829
120,567 259,829
Current assets
Debtors 5 713,155 1,316,927
Cash at bank and in hand 10,531 7,254
723,686 1,324,181
Creditors: amounts falling due within one year
6 (2,041,615) (1,500,576)
Net current liabilities (1,317,929) (176,395)
Total assets less current liabilities (1,197,362) 83,434
Creditors: Amounts falling due after more than one year
7 - (103,390)
NET LIABILITIES (1,197,362) (19,956)
Capital and reserves
Called up share capital 100 100
Profit and loss account (1,197,462) (20,056)
TOTAL EQUITY (1,197,362) (19,956)
The company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies for the year ended 31 December 2025.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities to comply with the Companies Act 2006 in respect to accounting records and the preparation of financial statements.
1
Company registration number: 12602104
Phase Biolabs Ltd
Balance sheet - continued
as at 31 December 2025
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered to the Registrar.
Signed by:
Mr D Ortega Raymundo, Director
30 September 2026
2
Phase Biolabs Ltd
Notes to the financial statements
for the year ended 31 December 2025
1 Company information
Phase Biolabs Ltd is a private company registered in England and Wales. Its registered number is 12602104. The company is limited by shares. Its registered office is Suite 2540, 37 Westminster Buildings, Nottingham, NG1 6LG.
2 Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” including the provisions of Section 1A “Small Entities” and the Companies Act 2006. The financial statements have been prepared under the historic cost convention.
Going concern
In preparing these financial statements, the director has assessed whether there are any material uncertainties related to events or conditions that cast significant doubt upon the company’s ability to continue as a going concern. In making this assessment, the director takes into account all available information about the future which is at least 12 months from the date that the financial statements are authorised for issue.
The director considers that the company has adequate resources to continue in business for the foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial statements.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes.
Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Plant and machinery etc.:
Lab Equipments - straight-line basis over 2 years
Computer Equipment - straight-line basis over 2 years
Taxation
Taxation for the year comprises current taxation. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
3
Phase Biolabs Ltd
Notes to the financial statements - continued
for the year ended 31 December 2025
2 Accounting policies - continued
Retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company’s pension scheme are charged to profit and loss in the period to which they relate.
3 Average number of employees
During the year the average number of employees was 11 (2024 - 12).
4 Tangible fixed assets
Plant and machinery etc.

£
Cost
At 1 January 2025 495,355
Additions 102,445
At 31 December 2025 597,800
Depreciation
At 1 January 2025 235,526
Charge for year 241,707
At 31 December 2025 477,233
Net book value
At 31 December 2025 120,567
At 31 December 2024 259,829
5 Debtors
2025 2024
£ £
Amounts falling due within one year
Trade debtors - 4,800
Taxation 39,056 183,438
Other debtors 642,141 1,080,136
Prepayments and accrued income 8,708 25,303
689,905 1,293,677
4
Phase Biolabs Ltd
Notes to the financial statements - continued
for the year ended 31 December 2025
5 Debtors - continued
2025 2024
£ £
Amounts falling due after more than one year
Other debtors 23,250 23,250
Total 713,155 1,316,927
6 Creditors: amounts falling due within one year
2025 2024
£ £
Trade creditors 27,053 31,430
Other creditors 2,010,411 1,452,548
Social security and other tax 4,151 13,054
Accruals and deferred income - 3,544
2,041,615 1,500,576
7 Creditors: amounts falling due after more than one year
2025 2024
£ £
Other creditors - 103,390
8 Advances, credit and guarantees granted to the director
There were no advances, credits, or guarantees granted to the directors during the period.
9 Related party transactions
At 31 December 2025, amounts owed to Phase Biolabs Inc. £2,009,531 (2024: £1,403,537).
10 Guarantees and other financial commitments
There were no financial guarantees or commitments, either ongoing or entered into during the period.
11 Off-balance sheet arrangements
The company had no off-balance sheet arrangements at year-end or at any stage during the period.
12 Controlling party
The company is controlled by the director.
5